Giulia Montuori

Freie Universität Berlin

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Freie Universität Berlin

Research Subjects

Research Interests

Giulia Montuori has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

Angelika Eggert
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
13 shared publications
Annette Künkele
Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
13 shared publications
Annika Lehmann
Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
13 shared publications
Anton George Henssen
Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
13 shared publications
Arend Koch
Department of Neuropathology Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin Berlin Germany
13 shared publications
Bartolomeo Bosco
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
13 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S1 contains FISH proteomics datasets
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S1 contains FISH proteomics datasets
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers
Open Access
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S7 demonstrates the impact of MYCN dosage on treatment response in neuroblastoma
Website
Google Scholar
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
by Giulia Montuori, Fengyu Tu, Di Qin, Rachel Schmargon, Elias Rodriguez-Fos, Konstantin Helmsauer, Hui Hui, Susmita Mandal, Karin Purshouse, Lara Fankhänel, et al.
Supplementary Figure S7 demonstrates the impact of MYCN dosage on treatment response in neuroblastoma

Show all